CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Commentary|Podcasts|May 19, 2026
Rethinking Pharma's Go-to-Market Formula
Author(s)Michael Christel, Mike Petroutsas
Mike Petroutsas, president and head of U.S. commercial at Astellas, explores the importance of insight-driven commercialization in reshaping how manufacturers engage patients, physicians and the broader healthcare ecosystem.
Advertisement
In this video episode of the Pharm Exec podcast, Mike Petroutsas, president and head of U.S. commercial at Astellas, shares the secrets to building a more agile commercial operating model — and mindset — equipped for today’s evolving engagement landscape.
Drawing on examples from GI oncology, retina care and women’s health, Petroutsas joins Mike Christel, group managing editor, MJH Life Sciences, to discuss how Astellas is tapping real-world insights, social listening and internal collaboration to refine commercialization efforts and boost patient engagement.
The PhRMA board member also offers perspective on commercial strategy implications from the Inflation Reduction Act and other healthcare policy, and touches as well on the career leadership lessons that guide his approach today.
Click below to listen to the audio version and subscribe to the Pharmaceutical Executive Podcast:
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
The Battle to Own the GLP-1 Patient Journey
3
Pharmaceutical Executive Daily: FDA Approves Fayuvi
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5